Personalis to Participate at the 19th Annual Needham Virtual Healthcare Conference
Get Alerts PSNL Hot Sheet
Join SI Premium – FREE
MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the 1-on-1 meetings at the upcoming 19th Annual Needham Virtual Healthcare Conference from Tuesday, April 14, 2020 through Wednesday, April 15, 2020.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis ImmunoID NeXT PlatformTM is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
View source version on businesswire.com: https://www.businesswire.com/news/home/20200331005808/en/
Investor Relations Contact:
Caroline Corner
[email protected]
415-202-5678
Media Contact:
Jennifer Havlek
[email protected]
www.personalis.com
650-752-1300
Source: Personalis, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novotech Strengthens Presence in Japan with Opening of Tokyo Office
- Alibaba Group Announced Pricing of HK$80 Billion Placing of New Shares in Hong Kong
- She Made it – the Youngest South African Woman to Swim the Channel
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Needham & Company, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share